KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Rating of "Buy" from Analysts

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) have been given a consensus recommendation of "Buy" by the nine brokerages that are currently covering the stock, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $26.29.

A number of analysts have commented on KALV shares. HC Wainwright upped their target price on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. JMP Securities upped their price target on shares of KalVista Pharmaceuticals from $19.00 to $27.00 and gave the stock a "market outperform" rating in a research report on Tuesday, July 8th. Leerink Partners upped their price target on shares of KalVista Pharmaceuticals from $18.00 to $20.00 and gave the stock an "outperform" rating in a research report on Monday, July 7th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th.

Insiders Place Their Bets

In related news, CEO Benjamin L. Palleiko sold 32,979 shares of the company's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $15.69, for a total transaction of $517,440.51. Following the completion of the transaction, the chief executive officer owned 369,595 shares in the company, valued at approximately $5,798,945.55. This represents a 8.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Paul K. Audhya sold 2,776 shares of the company's stock in a transaction on Monday, May 19th. The stock was sold at an average price of $11.84, for a total transaction of $32,867.84. Following the transaction, the insider owned 106,611 shares of the company's stock, valued at approximately $1,262,274.24. This represents a 2.54% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 48,878 shares of company stock valued at $723,617. 10.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Earned Wealth Advisors LLC bought a new position in KalVista Pharmaceuticals during the first quarter valued at $44,000. GAMMA Investing LLC raised its stake in shares of KalVista Pharmaceuticals by 567.3% in the first quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company's stock valued at $51,000 after acquiring an additional 3,767 shares during the period. CWM LLC raised its stake in shares of KalVista Pharmaceuticals by 12,636.1% in the first quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company's stock valued at $53,000 after acquiring an additional 4,549 shares during the period. Aquatic Capital Management LLC purchased a new stake in shares of KalVista Pharmaceuticals in the fourth quarter valued at $44,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of KalVista Pharmaceuticals by 666.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock valued at $54,000 after acquiring an additional 5,502 shares during the period.

KalVista Pharmaceuticals Stock Performance

Shares of KALV traded down $1.02 during mid-day trading on Friday, hitting $14.58. 1,013,514 shares of the company traded hands, compared to its average volume of 1,809,265. The stock has a 50-day moving average price of $13.20 and a two-hundred day moving average price of $11.66. KalVista Pharmaceuticals has a 1 year low of $7.30 and a 1 year high of $16.32. The stock has a market cap of $728.27 million, a price-to-earnings ratio of -3.95 and a beta of -0.04.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last announced its earnings results on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by ($2.86). During the same quarter last year, the firm earned ($1.07) EPS. On average, analysts forecast that KalVista Pharmaceuticals will post -3.56 EPS for the current year.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).